-
1.发明申请Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium 有权用于治疗与过量PHF或过量细胞内钙相关的疾病的鲨鱼软骨的制备公开(公告)号：US20070231404A1
公开(公告)日：2007-10-04
申请号：US11754524
申请日：2007-05-29
申请人： Peter Pang , Jacqueline Shan , Kam Chiu
发明人： Peter Pang , Jacqueline Shan , Kam Chiu
IPC分类号： A61K35/32
摘要： Shark cartilage extract has been shown to be an antagonist of parathyroid hypertensive factor (PHF). In view of this, shark cartilage extract can be used to treat conditions related to excessive PHF activity. Such diseases include hypertension and some other diseases related to intracellular calcium elevation. Methods for producing the shark cartilage extract and methods for administering the extract are disclosed.
摘要翻译： 鲨鱼软骨提取物已被证明是甲状旁腺高血压因子（PHF）的拮抗剂。 鉴于此，鲨鱼软骨提取物可用于治疗与过量PHF活性有关的病症。 这些疾病包括与细胞内钙升高相关的高血压和一些其它疾病。 公开了生产鲨鱼软骨提取物的方法和施用提取物的方法。
-
2.发明申请Processes of making north american ginseng fractions, products containing them, and use as immunomodulators 有权制作北美参人员分数，含有它们的产品，用作免疫调节剂的方法公开(公告)号：US20050196471A1
公开(公告)日：2005-09-08
申请号：US11114089
申请日：2005-04-26
申请人： Jacqueline Shan , Peter Pang , Buhan Huang , Lei Ling
发明人： Jacqueline Shan , Peter Pang , Buhan Huang , Lei Ling
CPC分类号： A61K39/39 , A61K36/258 , A61K2039/55583 , A61K2039/55588 , Y10S514/885
摘要： The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.
摘要翻译： 本发明涉及从北美人参（Panax quinquefolium）制备级分的化学方法和含有这些级分的药物组合物。 本发明的产品可用于刺激细胞因子和/或抗体的产生，或作为针对低免疫性特征的治疗剂，例如感冒，流感，慢性疲劳综合征，艾滋病和癌症。
-
公开(公告)号：US20120263806A1
公开(公告)日：2012-10-18
申请号：US13294043
申请日：2011-11-10
申请人： Sandra Miller , Jacqueline Shan
发明人： Sandra Miller , Jacqueline Shan
IPC分类号： A61K36/258 , A61P35/00 , A61P35/02
CPC分类号： A61K36/258
摘要： The invention is directed to ginseng fractions, methods of preventing or reducing hematological malignancies such as leukemia, and methods of elevating NK cells in a subject by administering to the subject an effective amount of a ginseng fraction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items. The fraction may be made from Panax quinquefolius or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.
摘要翻译： 本发明涉及人参级分，预防或减少诸如白血病的血液恶性肿瘤的方法，以及通过向受试者施用有效量的人参级分提高受试者的NK细胞的方法，包含该级分的药物组合物与 另一种药物或一种或多种药学上可接受的载体，包括食品。 该级分可以由Panax quinquefolius制备，或者可以选自CVT-E002，PQ2，PQ223和来自CVT-E002，PQ2和PQ223的纯化级分。
-
公开(公告)号：US20100260871A1
公开(公告)日：2010-10-14
申请号：US12600301
申请日：2007-05-16
申请人： Jacqueline Shan , Sandra C. Miller
发明人： Jacqueline Shan , Sandra C. Miller
IPC分类号： A61K36/258 , A61P35/02
CPC分类号： A61K36/258 , A61K31/715
摘要： The invention is directed to a method of treating hematological malignancies by administering to the subject ginseng fractions from North American ginseng (Panax quinquefolium). The present invention can be used to activate the proliferation of hemopoietic cells in a patient in need of treatment, or as a therapeutic targeted at conditions characterized by hematological malignancy, such as an abnormal proliferation of blood cells, lymphocytes, multiple myeloma, etc. The invention also includes a method of treating leukemia by activating the proliferation of natural killer (NK) cells and monocytes in the bone marrow and the spleen of the patient by administering at least one ginseng fraction selected from the group consisting of CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223. The present invention may be used to treat the hematological malignancy or as a supplement for patients undergoing chemotherapy or radiation therapy.
摘要翻译： 本发明涉及通过对来自北美人参（Panax quinquefolium）的受试者的人参成分施用治疗血液恶性肿瘤的方法。 本发明可用于激活需要治疗的患者中造血细胞的增殖，或用作以血液恶性肿瘤为特征的病症，如血细胞，淋巴细胞，多发性骨髓瘤等的异常增殖。 本发明还包括通过施用至少一种选自CVT-E002，PQ2，...的人参组分来激活患者的骨髓和脾脏中的天然杀伤（NK）细胞和单核细胞的增殖来治疗白血病的方法， PQ223和来自CVT-E002，PQ2和PQ223的纯化级分。 本发明可用于治疗血液恶性肿瘤或作为进行化疗或放射治疗的患者的补充。
-
5.发明授权Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression 有权含有N-炔丙基苯胺及其相关类似物以治疗神经变性和/或抑郁症的药物组合物公开(公告)号：US06593340B1
公开(公告)日：2003-07-15
申请号：US09794058
申请日：2001-02-28
申请人： Brian D. Sloley , Liana Urichuk , Lei Ling , Glen Baker , Ronald Coutts , Jacqueline Shan
发明人： Brian D. Sloley , Liana Urichuk , Lei Ling , Glen Baker , Ronald Coutts , Jacqueline Shan
IPC分类号： C07D21302
CPC分类号： C07C211/29 , C07C211/27
摘要： The present invention relates to N-propargylphentermine and its derivatives and the neuroprotective and anti-depressant activity of such compounds as well as therapeutic methods for such compounds.
摘要翻译： 本发明涉及N-炔丙基苯胺及其衍生物以及这些化合物的神经保护和抗抑郁活性以及这些化合物的治疗方法。
-
6.发明授权N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their analogs for the treatment of depression, anxiety and neurodegeneration 失效N1炔丙基肼，N2-炔丙基肼及其类似物用于治疗抑郁症，焦虑和神经退行性疾病
公开(公告)号：US6060516A
公开(公告)日：2000-05-09
申请号：US024113
申请日：1998-02-17
申请人： Ronald Coutts , Glen Baker , Duff Sloley , Jacqueline Shan , Peter K. T. Pang
发明人： Ronald Coutts , Glen Baker , Duff Sloley , Jacqueline Shan , Peter K. T. Pang
IPC分类号： A61R31/045
CPC分类号： C07C243/18
摘要： The present invention is directed to novel N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their salts in pharmaceutical compositions. The compounds according to the present invention have at least one of the following activities: monoamine oxidase-A inhibiting, monoamine oxidase-B inhibiting, anti-depressant, anti-anxiety and neuroprotectant activities. These compounds are useful as monoamine oxidase inhibitors and should be useful for the treatment of depression, anxiety and of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
摘要翻译： 本发明涉及新的N-炔丙基肼，其在药物组合物中的N-炔丙基肼及其盐。 根据本发明的化合物具有以下活性中的至少一种：单胺氧化酶-A抑制，单胺氧化酶-B抑制，抗抑郁，抗焦虑和神经保护作用。 这些化合物可用作单胺氧化酶抑制剂，并且可用于治疗抑郁症，焦虑症和神经变性疾病如帕金森病和阿尔茨海默病。
-
公开(公告)号：US20130243891A1
公开(公告)日：2013-09-19
申请号：US13886610
申请日：2013-05-03
申请人： Jacqueline Shan , Sandra Miller
发明人： Jacqueline Shan , Sandra Miller
IPC分类号： A61K36/258
CPC分类号： A61K36/258 , A61K31/715
摘要： The invention is directed to a method of treating hematological malignancies by administering to the subject ginseng fractions from North American ginseng (Panax quinquefolium). The present invention can be used to activate the proliferation of hemopoietic cells in a patient in need of treatment, or as a therapeutic targeted at conditions characterized by hematological malignancy, such as an abnormal proliferation of blood cells, lymphocytes, multiple myeloma, etc. The invention also includes a method of treating leukemia by activating the proliferation of natural killer (NK) cells and monocytes in the bone marrow and the spleen of the patient by administering at least one ginseng fraction selected from the group consisting of CVT-E002, PQ.sub.2, PQ.sub.223 and purified fractions from CVT-E002, PQ.sub.2 and PQ.sub.223. The present invention may be used to treat the hematological malignancy or as a supplement for patients undergoing chemotherapy or radiation therapy.
摘要翻译： 本发明涉及通过对来自北美人参（Panax quinquefolium）的受试者的人参成分施用治疗血液恶性肿瘤的方法。 本发明可用于激活需要治疗的患者中造血细胞的增殖，或用作以血液恶性肿瘤为特征的病症，如血细胞，淋巴细胞，多发性骨髓瘤等的异常增殖。 本发明还包括通过施用至少一种选自CVT-E002，PQ的人参组分来激活骨髓和患者的脾脏中的天然杀伤（NK）细胞和单核细胞的增殖来治疗白血病的方法。 sub.2，PQ2.23和来自CVT-E002，PQ2和PQ2.23的纯化级分。 本发明可用于治疗血液恶性肿瘤或作为进行化疗或放射治疗的患者的补充。
-
公开(公告)号：US08039027B1
公开(公告)日：2011-10-18
申请号：US11659537
申请日：2000-02-25
IPC分类号： A61K36/894 , A61K36/00
CPC分类号： A61K36/258 , A61K2300/00
摘要： Use of ginseng extracts designated CVT-E002, PQ2, PQ2A, PQ2B, PQ2C, PQ2D, and PQ223 in the preparation of a pharmaceutical composition suitable for treating an autoimmune disease.
摘要翻译： 使用指定为CVT-E002，PQ2，PQ2A，PQ2B，PQ2C，PQ2D和PQ223的人参提取物制备适于治疗自身免疫性疾病的药物组合物。
-
9.发明申请公开(公告)号：US20110086052A1
公开(公告)日：2011-04-14
申请号：US12919941
申请日：2009-02-27
CPC分类号： A61K36/258 , A61K36/25
摘要： The invention is directed to ginseng fractions and methods for activating innate and adaptive immune responses to prevent, treat or ameliorate a condition in a subject by administering to the subject an effective amount of a ginseng traction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers, or a food item comprising the fraction. The fraction may be made from Panax quinquefolius' or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.
摘要翻译： 本发明涉及用于通过向受试者施用有效量的人参牵引来激活天然和适应性免疫应答以预防，治疗或改善受试者的状况的方法，所述药物组合物包含所述部分与另一种组合 药物或一种或多种药学上可接受的载体，或包含该级分的食品。 该级分可以由Panax quinquefolius制备，或者可以选自CVT-E002，PQ2，PQ223和来自CVT-E002，PQ2和PQ223的纯化级分。
-
10.发明申请USE OF GINSENG FRACTIONS FOR PREVENTING OR REDUCING HEMATOLOGICAL MALIGNANCIES 审中-公开用于预防或减少血液恶性肿瘤的金山分子公开(公告)号：US20100221365A1
公开(公告)日：2010-09-02
申请号：US12394313
申请日：2009-02-27
申请人： Sandra C. Miller , Jacqueline Shan
发明人： Sandra C. Miller , Jacqueline Shan
IPC分类号： A61K36/258 , A61P7/00 , A61P35/02
CPC分类号： A61K36/258
摘要： The invention is directed to ginseng fractions, methods of preventing or reducing hematological malignancies such as leukemia, and methods of elevating NK cells in a subject by administering to the subject an effective amount of a ginseng fraction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items. The fraction may be made from Panax quinquefolius or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.
摘要翻译： 本发明涉及人参级分，预防或减少诸如白血病的血液恶性肿瘤的方法，以及通过向受试者施用有效量的人参级分提高受试者的NK细胞的方法，包含该级分的药物组合物与 另一种药物或一种或多种药学上可接受的载体，包括食品。 该级分可以由Panax quinquefolius制备，或者可以选自CVT-E002，PQ2，PQ223和来自CVT-E002，PQ2和PQ223的纯化级分。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.022 秒)
